Alpha Tau Medical, Ltd., an Israeli medical device company, raised a second funding round of undisclosed amount.
The company focuses on research, development, and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer. The Alpha DaRT technology was developed since 2003 by Prof. I. Kelson and Prof. Y. Keisari at the Tel Aviv University.
Preclinical trials on over 6,000 animals in numerous studies found the technology to be effective and safe in various tumor indications and anatomical areas.
The funding will be used to further develop the Alpha DaRT as a highlypotent and conformal treatment for 11 different types of solid tumors. Inserted directly into the tumor, Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) enables the treatment of solid tumors through alpha radiation.
The preliminary results of its first clinical study proved that Alpha DaRT has the ability to effectively destroy solid tumors with no systemic adverse events.
The Alpha DaRT treatment was done under local anesthesia, did not require any special shielding nor capital equipment and was carried out for a duration of about 60 minutes. After treating the first four patients, a safety report was submitted to summarize the results of the treatment.
The clinical study, which is led by Aron Popovtzer MD from Rabin Medical Center, Israel, tests the safety and efficacy of Alpha DaRT in patients with Squamous Cell Carcinoma (SCC) of the Skin and Head and Neck.
Alpha Tau Medical will soon start a similar study in Italy and is submitting research protocols for additional indications in Italy, Romania, France, and Germany. It is seeking to further initiate its first clinical study in the USA.